Editas Medicine, Inc.
Editas Medicine is a U.S.-based biotechnology company focused on developing gene-editing medicines using CRISPR-based platforms. Its work is centered on preclinical and early clinical programs, plus collaborations and licensing deals that generate most of its current revenue while it advances therapies for genetic and other serious diseases.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenuePreclinical and early clinical CRISPR medicines designed to treat serious genetic and other diseases.
Revenue from partner-funded development work, option packages, and milestone payments, mainly with BMS.
Annual and upfront license fees from technology access agreements such as the Vertex license.
Customers
Editas does not sell approved medicines today; its economic customers are pharmaceutical partners, licensees, and collaboration counterparties that pay for access to its gene-editing technology. The company’s future end customers would be patients and physicians in rare disease, liver, hematology, oncology, and autoimmune indications if any product is approved.
Large biopharma companies that pay for access to Editas' CRISPR platforms, development work, and option rights.
Companies such as Vertex that pay upfront or annual fees to use Editas-linked intellectual property and technology.
If programs are approved, hospitals, specialists, and patients in rare disease and liver indications would use the medicines.
Academic and industry partners that use Editas' platform technologies in partnered discovery and development programs.
Strategy
Editas is shifting toward a narrower, capital-efficient pipeline built around EDIT-401 and other preclinical gene-editing opportunities while using partnerships to fund development. It is also pursuing in-licensed delivery tools and collaboration structures that can extend runway, reduce internal manufacturing needs, and keep the platform relevant in a crowded gene-editing field.
The company needs a lead program to create future product value and validate its gene-editing platform.
Collaboration and license income currently funds operations and reduces dependence on product sales.
Effective delivery is a key bottleneck in in vivo gene editing and can improve program success rates.
As a preclinical biotech with no product sales, runway management is critical to avoid dilution and program delays.
Geography
Editas is headquartered in the United States and conducts most of its research, development, and corporate activity there. Its commercial exposure is global through collaborations and intellectual property disputes, including patent proceedings in Europe and other foreign jurisdictions, but the company currently has no manufacturing footprint of its own.
Risks
Editas faces the classic risks of an early-stage gene-editing biotech: clinical failure, regulatory delay, and uncertain commercial adoption if any candidate reaches market. Company-specific risks are amplified by patent disputes, dependence on collaborators and licensors, and the need to fund operations before product revenue exists.
- Clinical development failureImpact: CriticalLikelihood: High
The company is still preclinical/early clinical, so program outcomes are highly uncertain.
Exposure: EDIT-401 and other programs may never reach approval.
- Funding and liquidity riskImpact: HighLikelihood: High
The company does not expect meaningful recurring product revenue in the near term.
Exposure: May need additional capital before commercialization.
- Intellectual property disputesImpact: HighLikelihood: Medium
Some in-licensed patents face priority and validity challenges in the U.S. and Europe.
Exposure - Partner concentrationImpact: HighLikelihood: Low
Substantially all current revenue is expected from Vertex, BMS, and future collaborations.
Exposure: Loss or slowdown of a partner would reduce revenue and runway.
- Competition in gene editingImpact: MediumLikelihood: Low
Many large and well-funded biotech and pharma companies are pursuing similar indications.
Exposure: Competitors may reach the market first or develop better therapies.
Accounting
Judgemental itemsRevenue is recognized when option packages are delivered or milestones are achieved, creating quarter-to-quarter volatility.
Impact: Affects reported revenue timing and deferred revenue balances.
BMS payments received but not yet earned remain on the balance sheet until performance obligations are met.
Impact: Impacts future revenue recognition and balance sheet liabilities.
The discontinuation of reni-cel triggered severance, contract termination, and non-cash impairment costs.
Impact: Can materially distort operating expense trends and comparability.
Vertex annual fees are recognized over the relevant period under the license agreement.
Impact: Creates recurring revenue that is not tied to product sales.
Similar listed companies
Publicly listed companies with a comparable business focus.
Lisata Therapeutics, Inc
LSTA · Pharmaceutical Preparations
Lisata Therapeutics is a clinical-stage pharmaceutical company focused on developing certepetide, an investigational therapy designed to improve delivery of anti-cancer drugs into solid tumors.
Precision BioSciences, Inc
DTIL · Biological Products, (No Diagnostic Substances)
Precision BioSciences is a U.S.-based clinical-stage gene editing company built around its proprietary ARCUS genome editing platform.
Prime Medicine, Inc.
PRME · Biological Products, (No Diagnostic Substances)
Crispr Therapeutics AG
CRSP · Biological Products, (No Diagnostic Substances)
CRISPR Therapeutics AG is a gene-editing biopharmaceutical company built around CRISPR/Cas9 technology and the development of gene-based medicines for serious diseases.
MetaVia Inc.
MTVA · Pharmaceutical Preparations
Korro Bio, Inc.
KRRO · Pharmaceutical Preparations
Last updated: 24/09/2026